TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22170713
Drug: Conventional glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glycemic control (CGC; n=20; glucose goal, 180‐200 mg/dl)
Study: 22170713
Drug: Glucose-insulin-potassium (GIK;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium (GIK; n=10; glucose goal, 180‐200 mg/dl)
Study: 22170713
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (25 patients with glycemia below 140 mg/dl)
Study: 17505990
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of famotidine (10 mg) and omeprazole (20 mg)
Study: 11796648
Drug: Famotidine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (10 mg)
Study: 16173416
Drug: ROM regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROM regimen (one-dose regimen)
Study: 10520779
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg daily for 4 weeks
Study: 2502950
Drug: Topical mupirocin
Normalized name: mupirocin Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mupirocin applied three times daily
Study: 2502950
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin ethylsuccinate (30 to 50 mg/kg per day)
Study: 852890
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg pivampicillin tablets
Study: 852890
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg pivampicillin tablets (fasting)
Study: 852890
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg pivampicillin tablets (non-fasting)
Study: 30727810
Drug: Behavioral medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral medicine approach to physical therapy (BMPI)
Study: 20488431
Drug: bepotastine besilate
Normalized name: Bepotastine besilate
DrugBank: Bepotastine (DB04890)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bepotastine besilate ophthalmic solution 1.0%
Study: 20488431
Drug: bepotastine besilate
Normalized name: Bepotastine besilate
DrugBank: Bepotastine (DB04890)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bepotastine besilate ophthalmic solution 1.5%
Study: 19843481
Drug: bepotastine besilate
Normalized name: Bepotastine besilate
DrugBank: Bepotastine (DB04890)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bepotastine besilate ophthalmic solution 1.0% and 1.5%
Study: 3298412
Drug: human lymphoblastoid
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: human lymphoblastoid interferon (Wellferon) given for 28 consecutive days at a dosage ranging from 2.5 to 7.5 MU/m2 i.m.
Study: 23860273
Drug: TY-51924 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: TY-51924 (up to 30 mg/kg)
Study: 22439653
Drug: Intensive smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive smoking cessation counselling (face-to-face visits weekly for the first four weeks, monthly to six months, and two monthly to 12 months) and encouragement to attend a monthly smoking cessation support group.
Study: 18678295
Drug: High-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clopidogrel (600 mg loading immediately before PCI and 75 mg 2 times/day for 1 month)
Study: 18678295
Drug: Standard-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose clopidogrel (300 mg loading and 75 mg/day)
Study: 15620444
Drug: Gentamicin-collagen implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin-collagen implant
Study: 15620444
Drug: Control (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (routine intravenous antimicrobial prophylaxis)
Study: 10379218
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (trimethoprim TMP‐SMZ, nitrofurantoin, or a quinolone)
Study: 10379218
Drug: Intermittent patient‐administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent patient‐administered treatment (taken at the onset of symptoms)
Study: 2058162
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (8 capsules Ameu per day) for 21 days
Study: 2058162
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (8 capsules Ameu per day) for 56 days
Study: 26565005
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg lovastatin for 5 days
Study: 17718820
Drug: Intrathecal baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal baclofen (ITB) at doses of 12.5 microg, 20 microg, 25 microg, and 50 microg.
Study: 15733401
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin (n = 37)
Study: 15733401
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (n = 31)
Study: 7886187
Drug: Alcohol (0.83
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.83 ml ethanol/kg body weight)
Study: 2838344
Drug: Clofazimine (0.01‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofazimine (0.01‐5 micrograms/ml)
Study: 30158072
Drug: Amlodipine-based treatment
Normalized name: Amlodipine free base
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine-based treatment
Study: 10512261
Drug: Midazolam 1
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 1 mg IV and meperidine 50 mg
Study: 10512261
Drug: Ro 48-6791
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 48-6791 0.5 mg IV and meperidine 50 mg
Study: 10512261
Drug: Ro 48-6791
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 48-6791 1.0 mg IV alone
Study: 10512261
Drug: Ro 48-6791
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 48-6791 (both doses)
Study: 7717282
Drug: Digoxin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.25 mg once daily)
Study: 6988170
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g by intravenous injection prior to induction of anaesthesia)
Study: 28554517
Drug: Collagenase clostridium
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase clostridium histolyticum injection
Study: 22040192
Drug: Sertraline (25-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (25-150 mg/day)
Study: 20127533
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL of 0.25% levobupivacaine (LB group)
Study: 10473477
Drug: Drug counselling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug counselling
Study: 10473477
Drug: Treatment leaflets
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment leaflets
Study: 10473477
Drug: Counselling for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counselling for patients with major depressive disorder receiving doses >=75 mg
Study: 10473477
Drug: No counselling
Approvals — FDA: no, EMA: no, PMDA: no
Description: No counselling for patients with major depressive disorder receiving doses >=75 mg
Study: 8758157
Drug: Intramuscular bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular bupivacaine 12.5 mg
Study: 6918920
Drug: Oxygen inhalation
Normalized name: oxygen INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen inhalation at 2 liters per minute for 30 minutes
Study: 6918920
Drug: Oxygen inhalation
Normalized name: oxygen INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen inhalation at 4 liters per minute for 30 minutes
Study: 6918920
Drug: Oxygen inhalation
Normalized name: oxygen INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen inhalation at 6 liters per minute for 30 minutes
Study: 6918920
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oxygen inhalation)
Study: 30782008
Drug: DVD intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DVD intervention (the Sleep Easy Solution)
Study: 28448664
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg intravitreous bevacizumab
Study: 28448664
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg intravitreous bevacizumab
Study: 28448664
Drug: 0.063 mg
Normalized name: benzocaine 0.063 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.063 mg intravitreous bevacizumab
Study: 28448664
Drug: 0.031 mg
Normalized name: camphor 0.031 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.031 mg intravitreous bevacizumab
Study: 21339632
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of human rhGH administered from day 1 to day 7
Study: 21339632
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride (placebo) administered from day 1 to day 7
Study: 27222760
Drug: Paliperidone extended-release
Normalized name: Paliperidone Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone extended-release
Study: 11791086
Drug: HRT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT group (estradiol 2 mg and norethisterone acetate 1 mg)
Study: 10604491
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg HCTZ once daily
Study: 26858122
Drug: Durvalumab 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 20 mg/kg every 4 weeks plus tremelimumab 1 mg/kg
Study: 26858122
Drug: Durvalumab 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 20 mg/kg every 4 weeks plus tremelimumab 3 mg/kg
Study: 26858122
Drug: Durvalumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 3 mg/kg, 10 mg/kg, 15 mg/kg, or 20 mg/kg every 4 weeks, or 10 mg/kg every 2 weeks, plus tremelimumab 1 mg/kg, 3 mg/kg, or 10 mg/kg every 4 weeks for six doses then every 12 weeks for three doses
Study: 18372684
Drug: Inertial mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inertial mechanical loading (2.5 G at the feet decreasing to 1 G at the heart) for 60 min daily during 21 days of head-down bed rest
Study: 2508190
Drug: Misonidazole (MISO)
Normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misonidazole (MISO) 500 mg administered four hours prior to irradiation
Study: 73353
Drug: morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine (0.1 mg/kg)
Study: 20337772
Drug: Isotretinoin 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 0.3 mg/kg
Study: 15820533
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of metyrapone
Study: 15820533
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of cocaine
Study: 10482089
Drug: timolol 0.5%,
Normalized name: Timolol 0.5%, Bimatoprost 0.01% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: timolol 0.5%, twice daily
Study: 8739868
Drug: Antiseptic-mucolytic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiseptic-mucolytic saline
Study: 1754859
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily for 6 weeks (double-blind alternating treatment)
Study: 1754859
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 6 weeks (double-blind alternating treatment)
Study: 1754859
Drug: Ranitidine continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine continued for 4 weeks (single-blind treatment)
Study: 1754859
Drug: Placebo until
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo until relapse or maximum 8 weeks (single-blind treatment)
Study: 2883987
Drug: pindolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol (5 mg)
Study: 7102530
Drug: metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol (100 mg)
Study: 7102530
Drug: inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled fenoterol (0.4 mg)
Study: 31448738
Drug: Polypill group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill group (hydrochlorothiazide 12·5 mg, aspirin 81 mg, atorvastatin 20 mg, and enalapril 5 mg or valsartan 40 mg)
Study: 16143732
Drug: Telephone-administered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered cognitive-behavioral therapy (T-CBT)
Study: 10710122
Drug: UR-7247 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: UR-7247 2.5 mg
Study: 10710122
Drug: UR-7247 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: UR-7247 5 mg
Study: 10710122
Drug: UR-7247 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: UR-7247 10 mg
Study: 9015796
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg phenylalanine
Study: 8195856
Drug: Brodimoprim, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodimoprim, 200 mg once-a-day on the first day and 100 mg once-a-day on the following days
Study: 8195856
Drug: Cefaclor, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor, 40 mg/Kg/day in three doses
Study: 28089902
Drug: Olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg plus azelnidipine 16 mg
Study: 28089902
Drug: Olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg plus trichlormethiazide 1 mg
Study: 18339052
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate combined with vitamins C (500 mg) and B(6) (75 mg) and proline
Study: 12662184
Drug: RPR100893 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPR100893 (1 mg)
Study: 12662184
Drug: RPR100893 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPR100893 (5 mg)
Study: 12662184
Drug: RPR100893 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPR100893 (20 mg)
Study: 9385040
Drug: Acetaminophen (APAP)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP) administration (group A)
Study: 9385040
Drug: KAKKONTO at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAKKONTO at 100 mg/kg (group K) in rats
Study: 9385040
Drug: KAKKONTO at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAKKONTO at two different doses
Study: 1333097
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K treatment during the last 6 weeks prior to delivery
Study: 28641925
Drug: 3g oral
Normalized name: Fosfomycin Tromethamine 3g Oral granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g oral ManNAc
Study: 28641925
Drug: 6g oral
Normalized name: Sodium Sulfate 17.5g, Potassium Sulfate 3.13g, Magnesium Sulfate 1.6g Oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6g oral ManNAc
Study: 28641925
Drug: 10g oral
Normalized name: CytoCarn 10g Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10g oral ManNAc
Study: 25537481
Drug: Pasireotide (300-1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide (300-1,200 μg bid)
Study: 23887841
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (0.6 mg/kg rt-PA plus eptifibatide 135 mcg/kg bolus and a 2-hour infusion at 0.75 mcg/kg per minute)
Study: 23887841
Drug: Standard rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard rt-PA (0.9 mg/kg)
Study: 12837218
Drug: lamivudine treatment
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lamivudine treatment
Study: 8744700
Drug: Domperidone administration
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone administration
Study: 2666707
Drug: Dilzem (180‐300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilzem (180‐300 mg/daily)
Study: 2666707
Drug: Corinfar (30‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corinfar (30‐60 mg/daily)
Study: 998645
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% preparation
Study: 998645
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% preparation
Study: 998645
Drug: Lidocaine 0.25%
Normalized name: Bupivacaine Hydrochloride/Epinephrine/Lidocaine 0.25%-1 MG/1 ML-1% Injection Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.25% preparation
Study: 998645
Drug: Lidocaine 0.50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.50% preparation
Study: 998645
Drug: Lidocaine 0.75%
Normalized name: Bupivacaine Hydrochloride/Epinephrine/Lidocaine 0.75%-1 MG/1 ML-1% Injection Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.75% preparation
Study: 998645
Drug: Lidocaine 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.0% preparation
Study: 30731375
Drug: Antibiotics use
Normalized name: Antibiotics for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics use
Study: 28599898
Drug: Chlorhexidine-alcohol 26-mL
Normalized name: chlorhexidine / isopropyl alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine-alcohol 26-mL single-step applicator
Study: 28599898
Drug: Povidone-iodine aqueous
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine aqueous scrub and paint 236-mL wet skin tray
Study: 22511916
Drug: Intermittent oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent oral FTC/TDF (Monday, Friday and within 2 hours after sex)
Study: 22511916
Drug: Post-coital doses
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-coital doses of FTC/TDF
Study: 8053584
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil infusion at 0.2 microgram.kg‐1.h‐1
Study: 8053584
Drug: Intravenous sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sufentanil infusion at 0.2 microgram.kg‐1.h‐1
Study: 2927302
Drug: Glucose polymers
Normalized name: glucose polymers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose polymers (3 g.kg‐1 in a 50% solution)
Study: 31743467
Drug: Placebo 'dummy'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 'dummy' treatment
Study: 23859389
Drug: Inhaling ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaling ketamine 1 mg/kg (Group Ki)
Study: 23859389
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of ketamine 1 mg/kg (Group Kv)
Study: 23859389
Drug: Inhaling normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaling normal saline 10 ml (Group C)
Study: 2044734
Drug: Bricanyl Turbuhaler
Normalized name: terbutaline sulfate Oral Solution [Bricanyl]
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bricanyl Turbuhaler (dry powder terbutaline 0.5 mg q.i.d)
Study: 2044734
Drug: Bricanyl metered
Normalized name: terbutaline sulfate Oral Solution [Bricanyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bricanyl metered dose inhaler (MDI) (terbutaline 0.5 mg q.i.d)
Study: 25958709
Drug: Antibiotics discontinued
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics discontinued promptly after CRP level < 10 mg/L in group Ia
Study: 25958709
Drug: Antibiotics continued
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics continued until all bacterial cultures were negative in group Ib
Study: 25958709
Drug: Antibiotics continued
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics continued until CRP < 10 mg/L in group IIa
Study: 25958709
Drug: Antibiotics continued
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics continued until all bacterial cultures were negative in group IIb
Study: 19857666
Drug: Mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolic acid (MPA) C(0) levels below 1.0 to 1.5 microg/mL at day 7
Study: 19857666
Drug: MPAG C(0)
Normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MPAG C(0) levels above 100 to 150 microg/mL at day 7
Study: 15113721
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (25 mg Zn)
Study: 7913986
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) administered antenatally, intrapartum, and postnatally
Study: 25432081
Drug: Pazopanib 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 5 mg/ml instilled 3 times daily (n = 72)
Study: 25432081
Drug: Pazopanib 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 5 mg/ml instilled 4 times daily (n = 74)
Study: 25432081
Drug: Pazopanib 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 10 mg/ml instilled 2 times daily (n = 73)
Study: 25432081
Drug: Pazopanib 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 10 mg/ml instilled 3 times daily (n = 73)
Study: 25432081
Drug: Pazopanib 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 10 mg/ml instilled 4 times daily (n = 72)
Study: 25432081
Drug: Ranibizumab injection
Normalized name: ranibizumab Injection
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab injection administered once every 4 weeks (n = 73)